Through recent acquisitions and their relationship with CytRx (CYTR), VXCL is in a position to benefit from the drive to maximize the effectiveness of agents and speed-up their action with delivery agents, a key aspect of their portfolio....
(related excerpts from the 10k -- available at freedgar.com...must type in company name "Vaxcel", not the ticker symbol)
PATENTS AND PROPRIETARY TECHNOLOGY--
Vaxcel actively seeks patent protection for its technologies,
processes, uses, and ongoing improvements and considers its patents and other
intellectual property to be critical to its business.
Vaxcel has received a worldwide, exclusive licensefrom CytRx for the
use of a series of certain copolymers as a vaccine adjuvant/delivery system.
See Item 13 - "Certain Relationships and Related Transactions." These patents
and patent applications contain claims directed to the use of copolymers as
vaccine adjuvants/delivery systems and the use of the copolymers in any vaccine
preparation.
The compositions and methods for the administration of bioactive
agents to and through the Peyer's Patches by means of microencapsulation in
biocompatible, biodegradable microspheres of 1-10 microns in diameter are
protected by issued patents, pending United States patent applications, and foreign counterparts held by Southern Research
Institute ("SRI") and the University of Alabama at Birmingham ("UAB"). By means
of the Merger with Zynaxis, this microencapsulation technology is exclusively
licensed to Vaxcel in the field of oral vaccine delivery. See Item 13 -
"Certain Relationships and Related Transactions."
More to come ...
|
